Eagle Vindicated On Vasopressin With US Federal Circuit Decision
US Appeals Court Affirms Favorable Finding Of Non-Infringement
Executive Summary
Endo’s woes show no sign of abating, with the US Court of Appeals for the Federal Circuit shooting down its appeal against a finding of non-infringement for two key patents shielding its Vasostrict injectable.
You may also be interested in...
Generic Pylera Leads Charge As Endo Aims To Fix Up Floundering Business
Endo has launched the first generic version of Allergan’s H. pylori treatment Pylera and plans to launch around 10 products from its sterile injectables and generics businesses this year.
Stricken Endo Eyes $6bn Debt Cut With Bankruptcy Filing And Restructuring
A group of Endo debtholders are looking to buy the firm out of bankruptcy, with an initial $6bn bid for the stricken firm that envisions setting aside more than half-a-billion dollars for opioid-related claims. Meanwhile, Endo has reached an agreement-in-principle to resolve opioid-related claims.
Multiple Vasostrict ANDAs Rival Eagle In Competitive Market
Amphastar, Amneal and Aurobindo are among ANDA sponsors confirming USFDA approval for generic versions of Endo’s Vasostrict (vasopressin) 20 units/ml single-dose vial – as first mover Eagle Pharmaceuticals remains locked in patent-litigation proceedings with the originator.